Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 101 articles:
HTML format
Text format



Single Articles


    September 2017
  1. RAJAN P, Sooriakumaran P, Nyberg T, Akre O, et al
    Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study.
    J Clin Oncol. 2017 Sep 20:JCO2016707794. doi: 10.1200/JCO.2016.70.7794.
    PubMed     Text format     Abstract available


    August 2017
  2. BAIK SH, Kury FSP, McDonald CJ
    Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
    J Clin Oncol. 2017 Aug 25:JCO2017726109. doi: 10.1200/JCO.2017.72.6109.
    PubMed     Text format     Abstract available


  3. MUCCI LA, Kantoff PW
    Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?
    J Clin Oncol. 2017 Aug 17:JCO2017747915. doi: 10.1200/JCO.2017.74.7915.
    PubMed     Text format    


  4. EISENBERGER M, Hardy-Bessard AC, Kim CS, Geczi L, et al
    Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
    J Clin Oncol. 2017 Aug 15:JCO2016721076. doi: 10.1200/JCO.2016.72.1076.
    PubMed     Text format     Abstract available


  5. ZHANG T, Armstrong AJ
    The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017 Aug 15:JCO2017747931. doi: 10.1200/JCO.2017.74.7931.
    PubMed     Text format    


  6. LARSEN SB, Dehlendorff C, Skriver C, Dalton SO, et al
    Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer.
    J Clin Oncol. 2017 Aug 14:JCO2016718981. doi: 10.1200/JCO.2016.71.8981.
    PubMed     Text format     Abstract available


  7. XIE W, Regan MM, Buyse M, Halabi S, et al
    Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    J Clin Oncol. 2017 Aug 10:JCO2017739987. doi: 10.1200/JCO.2017.73.9987.
    PubMed     Text format     Abstract available


    July 2017
  8. OUDARD S, Fizazi K, Sengelov L, Daugaard G, et al
    Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    J Clin Oncol. 2017 Jul 28:JCO2016721068. doi: 10.1200/JCO.2016.72.1068.
    PubMed     Text format     Abstract available


    June 2017
  9. HARMON SA, Perk T, Lin C, Eickhoff J, et al
    Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.
    J Clin Oncol. 2017 Jun 27:JCO2017722348. doi: 10.1200/JCO.2017.72.2348.
    PubMed     Text format     Abstract available


  10. ANTONARAKIS ES, Tagawa ST, Galletti G, Worroll D, et al
    Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naive, Metastatic, Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017 Jun 20:JCO2017724138. doi: 10.1200/JCO.2017.72.4138.
    PubMed     Text format     Abstract available


  11. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Text format     Abstract available


  12. SPRATT DE, Yousefi K, Deheshi S, Ross AE, et al
    Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.
    J Clin Oncol. 2017;35:1991-1998.
    PubMed     Text format     Abstract available


    May 2017
  13. HOFFMAN RM, Lo M, Clark JA, Albertsen PC, et al
    Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
    J Clin Oncol. 2017 May 11:JCO2016706317. doi: 10.1200/JCO.2016.70.6317.
    PubMed     Text format     Abstract available


  14. PARIKH RR, Kim IY
    Can Genomic Data Guide the Postoperative Management of Prostate Cancer?
    J Clin Oncol. 2017 May 4:JCO2017724849. doi: 10.1200/JCO.2017.72.4849.
    PubMed     Text format    


  15. VAN DE WAL M, Thewes B, Gielissen M, Speckens A, et al
    Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial.
    J Clin Oncol. 2017 May 4:JCO2016705301. doi: 10.1200/JCO.2016.70.5301.
    PubMed     Text format     Abstract available


  16. LOEB S, Folkvaljon Y, Damber JE, Alukal J, et al
    Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
    J Clin Oncol. 2017;35:1430-1436.
    PubMed     Text format     Abstract available


    April 2017
  17. LECARPENTIER J, Silvestri V, Kuchenbaecker KB, Barrowdale D, et al
    Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
    J Clin Oncol. 2017 Apr 27:JCO2016694935. doi: 10.1200/JCO.2016.69.4935.
    PubMed     Text format     Abstract available


  18. VIRGO KS, Basch E, Loblaw DA, Oliver T, et al
    Second-Line Hormonal Therapy for Men With Chemotherapy-Naive, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
    J Clin Oncol. 2017 Apr 25:JCO2017728030. doi: 10.1200/JCO.2017.72.8030.
    PubMed     Text format     Abstract available


  19. PERNAR CH, Downer MK, Wilson KM, Stampfer MJ, et al
    Vasectomy and Risk of Prostate Cancer: How to Weigh Current Evidence.
    J Clin Oncol. 2017;35:1272-1273.
    PubMed     Text format    


  20. BUBLEY GJ, Balk SP
    Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.
    J Clin Oncol. 2017 Apr 17:JCO2017728808. doi: 10.1200/JCO.2017.72.8808.
    PubMed     Text format    


  21. ANTONARAKIS ES, Lu C, Luber B, Wang H, et al
    Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    J Clin Oncol. 2017 Apr 6:JCO2016701961. doi: 10.1200/JCO.2016.70.1961.
    PubMed     Text format     Abstract available


    March 2017
  22. YU JB
    Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales.
    J Clin Oncol. 2017 Mar 29:JCO2017727016. doi: 10.1200/JCO.2017.72.7016.
    PubMed     Text format    


  23. ARCANGELI G, Saracino B, Arcangeli S, Gomellini S, et al
    Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.
    J Clin Oncol. 2017 Mar 29:JCO2016704189. doi: 10.1200/JCO.2016.70.4189.
    PubMed     Text format     Abstract available


  24. DALELA D, Santiago-Jimenez M, Yousefi K, Karnes RJ, et al
    Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.
    J Clin Oncol. 2017 Mar 28:JCO2016699918. doi: 10.1200/JCO.2016.69.9918.
    PubMed     Text format     Abstract available


  25. GARZOTTO M
    Is Low-Risk Prostate Cancer More Indolent in Younger Patients?
    J Clin Oncol. 2017 Mar 27:JCO2017723684. doi: 10.1200/JCO.2017.72.3684.
    PubMed     Text format    


  26. LEAPMAN MS, Cowan JE, Nguyen HG, Shinohara KK, et al
    Active Surveillance in Younger Men With Prostate Cancer.
    J Clin Oncol. 2017 Mar 27:JCO2016680058. doi: 10.1200/JCO.2016.68.0058.
    PubMed     Text format     Abstract available


  27. CHIN J, Rumble RB, Kollmeier M, Heath E, et al
    Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
    J Clin Oncol. 2017 Mar 27:JCO2016720466. doi: 10.1200/JCO.2016.72.0466.
    PubMed     Text format     Abstract available


  28. CATTON CN, Lukka H, Gu CS, Martin JM, et al
    Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.
    J Clin Oncol. 2017 Mar 15:JCO2016717397. doi: 10.1200/JCO.2016.71.7397.
    PubMed     Text format     Abstract available


  29. MASON MD, Clarke NW, James ND, Dearnaley DP, et al
    Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
    J Clin Oncol. 2017 Mar 13:JCO2016690677. doi: 10.1200/JCO.2016.69.0677.
    PubMed     Text format     Abstract available


  30. SAAD F
    Bone-Targeted Therapy in Prostate Cancer in 2017: Lost Opportunities, Confusion, and Controversy.
    J Clin Oncol. 2017 Mar 13:JCO2017722793. doi: 10.1200/JCO.2017.72.2793.
    PubMed     Text format    


  31. SMITH BYRNE K, Castano JM, Chirlaque MD, Lilja H, et al
    Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC).
    J Clin Oncol. 2017 Mar 6:JCO2016700062. doi: 10.1200/JCO.2016.70.0062.
    PubMed     Text format     Abstract available


    February 2017
  32. D'AMICO AV
    Active Surveillance Versus Treatment of Prostate Cancer: Should Metastasis Be the Primary End Point?
    J Clin Oncol. 2017 Feb 27:JCO2016709527. doi: 10.1200/JCO.2016.70.9527.
    PubMed     Text format    


    January 2017
  33. BEER TM, Kwon ED, Drake CG, Fizazi K, et al
    Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017;35:40-47.
    PubMed     Text format     Abstract available


  34. SENDUR MA, Yalcin B
    Does Enzalutamide Really Reduce the Risk of Progression Compared With Bicalutamide in Patients With Castration-Resistant Prostate Cancer?
    J Clin Oncol. 2017;35:122.
    PubMed     Text format    


  35. MICHELS J
    Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial-There is No Significant Reduction in Death (Yet).
    J Clin Oncol. 2017;35:123.
    PubMed     Text format    


  36. KIM W, Fong L
    Can Prostate Cancer Really Respond to Immunotherapy?
    J Clin Oncol. 2017;35:4-5.
    PubMed     Text format    


    December 2016
  37. TOSOIAN JJ, Carter HB
    Active Surveillance of Localized Prostate Cancer: Acknowledging Uncertainty.
    J Clin Oncol. 2016;34:4452.
    PubMed     Text format    


  38. ALBERTSEN PC
    Risk Factors for Prostate Cancer: Which Are Truly Predictive of Clinically Significant Disease?
    J Clin Oncol. 2016;34:4310-4311.
    PubMed     Text format    


  39. TANGEN CM, Goodman PJ, Till C, Schenk JM, et al
    Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.
    J Clin Oncol. 2016;34:4338-4344.
    PubMed     Text format     Abstract available


    November 2016
  40. CHAMBERS SK, Occhipinti S, Foley E, Clutton S, et al
    Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2016 Nov 21:JCO2016688788.
    PubMed     Text format     Abstract available


  41. KHOSROW-KHAVAR F, Rej S, Yin H, Aprikian A, et al
    Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer.
    J Clin Oncol. 2016 Nov 21:JCO2016696203.
    PubMed     Text format     Abstract available


    September 2016
  42. KANTOFF PW, Gulley JL, Pico-Navarro C
    Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2016 Sep 19. pii: JCO697748.
    PubMed     Text format    


  43. JACOBS EJ, Anderson RL, Stevens VL, Newton CC, et al
    Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    J Clin Oncol. 2016 Sep 19. pii: JCO662361.
    PubMed     Text format     Abstract available


  44. DU J, Yan W, Mai Z
    Dose-Escalated External-Beam Radiotherapy for Prostate Cancer: Two Ensuing Questions.
    J Clin Oncol. 2016 Sep 12. pii: JCO685859.
    PubMed     Text format    


  45. GIACALONE NJ, Wu J, Chen MH, Renshaw A, et al
    Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial.
    J Clin Oncol. 2016 Sep 6. pii: JCO684530.
    PubMed     Text format     Abstract available


    August 2016
  46. ZUMSTEG ZS, Daskivich TJ, Sandler HM
    Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy.
    J Clin Oncol. 2016 Aug 29. pii: JCO692509.
    PubMed     Text format     Abstract available


  47. STISH BJ, Pisansky TM, Harmsen WS, Davis BJ, et al
    Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.
    J Clin Oncol. 2016 Aug 1. pii: JCO683425.
    PubMed     Text format     Abstract available


    July 2016
  48. ROCA E, Valcamonico F, Amoroso V, Antonelli A, et al
    Serum Vitamin D and Prostate Cancer Prognosis: The Story Continues.
    J Clin Oncol. 2016 Jul 25. pii: JCO682617.
    PubMed     Text format    


  49. MITTAKANTI HR, Thomas IC, Chung BI, Sonn GA, et al
    Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries.
    J Clin Oncol. 2016 Jul 25. pii: JCO689216.
    PubMed     Text format    


  50. LOGOTHETIS CJ, Aparicio AM
    Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?
    J Clin Oncol. 2016 Jul 18. pii: JCO684738.
    PubMed     Text format    


  51. PENSON DF, Resnick MJ
    Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening.
    J Clin Oncol. 2016 Jul 18. pii: JCO687194.
    PubMed     Text format    


  52. SMITH M, De Bono J, Sternberg C, Le Moulec S, et al
    Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    J Clin Oncol. 2016 Jul 11. pii: JCO655597.
    PubMed     Text format     Abstract available


  53. ALUMKAL JJ, Beer TM
    Raising the Bar for Therapeutic Trials in Advanced Prostate Cancer.
    J Clin Oncol. 2016 Jul 11. pii: JCO680439.
    PubMed     Text format    


    June 2016
  54. RUSTHOVEN CG, Jones BL, Flaig TW, Crawford ED, et al
    Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    J Clin Oncol. 2016 Jun 20. pii: JCO674788.
    PubMed     Text format     Abstract available


  55. LOEB S
    Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening.
    J Clin Oncol. 2016 Jun 20. pii: JCO682138.
    PubMed     Text format    


  56. STERNBERG C, Armstrong A, Pili R, Ng S, et al
    Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2016 Jun 13. pii: JCO669697.
    PubMed     Text format     Abstract available


  57. PRESTON MA, Batista JL, Wilson KM, Carlsson SV, et al
    Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.
    J Clin Oncol. 2016 Jun 13. pii: JCO667527.
    PubMed     Text format     Abstract available


    April 2016
  58. NYAME YA, Murphy AB, Bowen DK, Jordan G, et al
    Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.
    J Clin Oncol. 2016;34:1345-9.
    PubMed     Text format     Abstract available


  59. ZIETMAN AL
    Making Radiation Therapy for Prostate Cancer More Economical and More Convenient.
    J Clin Oncol. 2016 Apr 18. pii: JCO673764.
    PubMed     Text format    


  60. DINH KT, Reznor G, Muralidhar V, Mahal BA, et al
    Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer.
    J Clin Oncol. 2016 Apr 11. pii: JCO641969.
    PubMed     Text format     Abstract available


  61. SCHOLZ MC, Lam RY, Turner JS
    Query About the Frequency of Biopsy Complications.
    J Clin Oncol. 2016;34:1284.
    PubMed     Text format    


  62. D'AMICO AV
    Reply to M.C. Scholz et al.
    J Clin Oncol. 2016;34:1284.
    PubMed     Text format    


  63. CARTER HB
    Reply to M.C. Scholz et al.
    J Clin Oncol. 2016;34:1284.
    PubMed     Text format    


  64. CARMONA R, Zakeri K, Green G, Hwang L, et al
    Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events.
    J Clin Oncol. 2016;34:1270-7.
    PubMed     Text format     Abstract available


  65. LEE WR, Dignam JJ, Amin MB, Bruner DW, et al
    Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
    J Clin Oncol. 2016 Apr 4. pii: JCO670448.
    PubMed     Text format     Abstract available


  66. MCKAY RR, Zurita AJ, Werner L, Bruce JY, et al
    A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.
    J Clin Oncol. 2016 Apr 4. pii: JCO653154.
    PubMed     Text format     Abstract available


    March 2016
  67. STEIN MN, Jang TL
    Striving Toward a Cure for Prostate Cancer.
    J Clin Oncol. 2016 Mar 28. pii: JCO663146.
    PubMed     Text format    


  68. DOSORETZ AP, Yu JB
    Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer.
    J Clin Oncol. 2016 Mar 21. pii: JCO663237.
    PubMed     Text format     Abstract available


  69. POLLACK A, Abramowitz MC
    Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer.
    J Clin Oncol. 2016 Mar 14. pii: JCO662320.
    PubMed     Text format    


  70. BOLLA M, Maingon P, Carrie C, Villa S, et al
    Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.
    J Clin Oncol. 2016 Mar 14. pii: JCO648055.
    PubMed     Text format     Abstract available


  71. HALABI S, Kelly WK, Ma H, Zhou H, et al
    Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2016 Mar 7. pii: JCO657270.
    PubMed     Text format     Abstract available


    February 2016
  72. SCHER HI, Morris MJ, Stadler WM, Higano C, et al
    Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
    J Clin Oncol. 2016 Feb 22. pii: JCO642702.
    PubMed     Text format     Abstract available


  73. MCGINTY HL
    Unlocking Electronic Medical Record Data to Identify Possible Connections Between Cancer and Cognitive Declines.
    J Clin Oncol. 2016;34:530-2.
    PubMed     Text format    


  74. NEAD KT, Gaskin G, Chester C, Swisher-McClure S, et al
    Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.
    J Clin Oncol. 2016;34:566-71.
    PubMed     Text format     Abstract available


  75. CHEN RC, Rumble RB, Loblaw DA, Finelli A, et al
    Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
    J Clin Oncol. 2016 Feb 16. pii: JCO657759.
    PubMed     Text format     Abstract available


  76. SCHER HI, Heller G, Molina A, Kheoh T, et al
    Reply to A. Addeo and A. Bahl.
    J Clin Oncol. 2016;34:387-8.
    PubMed     Text format    


    January 2016
  77. PENSON DF, Armstrong AJ, Concepcion R, Agarwal N, et al
    Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    J Clin Oncol. 2016 Jan 25. pii: JCO649285.
    PubMed     Text format     Abstract available


  78. HUSSAIN M, Tangen C, Higano C, Vogelzang N, et al
    Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.
    J Clin Oncol. 2016;34:280-5.
    PubMed     Text format     Abstract available


  79. DEAL AM, Williams GR, Guerard EJ, Pergolotti M, et al
    Physical activity communication between oncology providers and patients with early stage breast, colon or prostate cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  80. LEONG N, Hodgson S, Wambolt E, Hildebrand C, et al
    Development and evaluation of the TrueNTH-Prostate Cancer Canada electronic Library for Improved (urinary and bowel) Function post Treatment (TrueNTH-PCC-eLIFT).
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  81. ZAROWSKI C, Dayan M, Pollock P, Elliott S, et al
    Utilization of sexual health and pelvic floor physiotherapy services in Vancouver's Prostate Cancer Supportive Care (PCSC) Program.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  82. BORSCH C, Garg B, Dobek JC, Doggett R, et al
    Falls and frailty in prostate cancer survivors on androgen deprivation therapy.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  83. POLLOCK P, Wassersug RJ, Zarowski C, Dayan M, et al
    Successful implementation of a disease-specific survivorship program for men with prostate cancer (PC) and their partners.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  84. LIN DW, Karsh LI, Shevrin DH, Shore ND, et al
    The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  85. FRANKLAND J, Brodie H, Cooke D, Pickering R, et al
    The True NTH Prostate Cancer Survivorship Care programme: Development and evaluation of a model for delivering follow-up care to men with prostate cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available



  86. Thoughts and experience 10 years post surgery from a cancer researcher and survivor: The burdens of a prostate cancer survivor.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  87. MAY S, Feller JF
    Transrectal MR-guided laser focal therapy of recurrent prostate cancer in a patient post-proton therapy: A case study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  88. PORTER KR, Slezak JM, Chien GW, Jacobsen SJ, et al
    Racial and ethnic variation in baseline health-related quality of life scores prior to prostate cancer treatment.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  89. DU L, Ahmed IA, Morgans AK
    Education practices in prostate cancer: A comparison of patient and caregiver experiences.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  90. TSANG V, Palmer-Hague JL, Wassersug RJ, Nasiopoulos E, et al
    Using eye-tracking to quantify the impact of prostate cancer treatments on male libido: A pilot study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  91. NEWTON RU, Culos-Reed SN, Faithfull S, Lambert S, et al
    An international, population-level initiative to promote healthy lifestyle practices among prostate cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  92. MALLAPAREDDI A, Ruterbusch J, Reamer E, Eggly S, et al
    Active surveillance for early stage prostate cancer: What do men and their partners think?
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  93. GRANDE D, Crossette L, Bekelman JE, Pollack CE, et al
    Understanding the impact of primary care providers on treatment decisions for men with localized prostate cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  94. BIDDLE H, Hunnicutt BA, Trenkner S
    SEASONS: A prospective study assessing the physical, psychosocial, spiritual, and financial needs of patients with breast and prostate cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


    December 2015
  95. WANG X, Harshman LC, Xie W, Nakabayashi M, et al
    Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
    J Clin Oncol. 2015 Dec 14. pii: JCO625988.
    PubMed     Text format     Abstract available


    November 2015
  96. PARK JC, Eisenberger MA
    Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?
    J Clin Oncol. 2015 Nov 30. pii: JCO641019.
    PubMed     Text format    


  97. ADDEO A, Bahl A
    Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?
    J Clin Oncol. 2015 Nov 23. pii: JCO628537.
    PubMed     Text format    


  98. MURPHY DR, Wu L, Thomas EJ, Forjuoh SN, et al
    Electronic Trigger-Based Intervention to Reduce Delays in Diagnostic Evaluation for Cancer: A Cluster Randomized Controlled Trial.
    J Clin Oncol. 2015;33:3560-7.
    PubMed     Text format     Abstract available


    October 2015
  99. LU K
    The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel?
    J Clin Oncol. 2015;33:3221.
    PubMed     Text format    


  100. FIZAZI K, Dreicer R
    Reply to K. Lu.
    J Clin Oncol. 2015;33:3222.
    PubMed     Text format    


  101. MORRIS MJ
    Reply to K. Lu.
    J Clin Oncol. 2015;33:3222-3.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: